Introduction
============

Introduction of adjuvant treatment has led to improved treatment outcomes in cervical cancer; however, 10%-20% of patients still experience treatment failure after radical surgery followed by recommended adjuvant treatment \[[@b1-crt-2015-085]-[@b3-crt-2015-085]\]. This recurrent disease has an unfavorable prognosis, with a 5-year survival rate of 35% \[[@b4-crt-2015-085]\]. Given the grave prognosis, some researchers have evaluated the efficacy of consolidative chemotherapy (CTx) after adjuvant treatment in patients with high-risk factors such as lymph node (LN) status, parametrial (PM) invasion, bulky tumor, and resection margin \[[@b5-crt-2015-085],[@b6-crt-2015-085]\]. However, the role of consolidative CTx remains unclear in these patients \[[@b7-crt-2015-085],[@b8-crt-2015-085]\]. Identification of patients who might benefit from consolidative CTx after traditional adjuvant treatment first requires predictive markers for high risk of recurrence. However, unlike in the surgery-only treatment, there is no established prognostic factor for patients treated with radical hysterectomy followed by adjuvant treatment.

Underestimating the value of LN metastasis is a major weakness of the staging system for cervical cancer. The International Federation of Gynecology and Obstetrics (FIGO) staging system does not consider LN status, while the American Joint Committee on Cancer staging system simply stratifies it as N0 or N1 \[[@b9-crt-2015-085]\]. However, estimating risk for recurrence of other malignant solid tumors according to LN status suggests that patient's prognosis could be significantly influenced by LN burden, such as the number, location, or log odds of pathologic LNs. For example, Monk et al. \[[@b10-crt-2015-085]\] reported on the difference in clinical prognosis between single LN metastasis and ≥ 2 LN metastasis after radical hysterectomy followed by adjuvant radiotherapy (RT). Kidd et al. \[[@b11-crt-2015-085]\], who studied LN staging by positron emission tomography, demonstrated that disease-free survival (DFS) could be stratified by the most distant level of LN metastasis as none, pelvic, para-aortic, or supraclavicular area (p \< 0.001). Demirci et al. \[[@b12-crt-2015-085]\] reported that the LN ratio (LNR) had clinical importance not only for overall survival (OS), but also for local control and DFS after adjuvant treatment in FIGO IB-II staged cervical cancer. More recently, the prognostic impacts of log odds of positive LNs (LODDs), the log of odds between number of positive LNs, and number of negative LNs have been studied in gastrointestinal cancers. However, the method for assessing LN status showing the most correlation with the prognosis for cervical cancer has not been determined. Therefore, we compared the prognostic value of various methods for assessing LN status, including simple pathologic N stage, the location and number of positive LNs, LNR, and LODDs in patients with high-risk cervical cancer treated with radical surgery and adjuvant treatment, in order to define subgroups at risk of high recurrence.

Materials and Methods
=====================

1. Patients
-----------

From a local database, consecutive 76 patients with histologically proven cervical cancer who had been referred for postoperative RT after radical surgery from January 2004 to June 2012 were identified. Ten patients who did not undergo radical hysterectomy and pelvic LN dissection were excluded. Among 66 patients, only 50 patients with one or more high risk factors, including tumor involvement at the surgical margin, PM invasion, or LN metastasis, were included in the analysis for homogeneity. Patients' medical records were reviewed for collection of data on demographics, clinicopathologic factors, treatment, and survival outcomes. Information collected included patients' complete blood count, including the differential and serum levels of tumor markers before surgery. The location and number of metastatic LNs were obtained from pathologic reports. According to the location of positive LNs, LNs were classified as upper LNs (common iliac LNs or higher) or lower LNs (below common iliac LNs). The LNR was calculated as the number of pathologic LNs divided by the number of harvested LNs. LODDs is defined as log((No. of positive LNs+0.5)/(No. of harvested LNs--No.of postivie LNs+0.5)).

All patients were restaged according to FIGO 2008 staging system \[[@b13-crt-2015-085]\]. Treatment-related complications were graded using the Common Terminology Criteria for Adverse Events ver. 4.03. This study was approved by our institutional review board.

2. Treatment
------------

All patients underwent radical hysterectomy with pelvic LN dissection, with or without para-aortic LN sampling or dissection at the discretion of the treating physician. Postoperative RT was delivered with megavoltage photons by a linear accelerator, using a traditional four-field technique covering the whole pelvis. In six patients with microscopic metastasis in the paraaortic area, radiation portals for the paraaortic region were added. One patient with involvement of the vaginal resection margin underwent intracavitary RT to the vaginal stump with 15 Gy over five fractions. The median total dose and fraction were 50.4 Gy (range, 50 to 55.8 Gy) and 28 fractions (range, 25 to 31 fractions).

CTx was provided concurrently to 43 patients, and no patient underwent consolidative CTx after RT. Almost all patients (93%, 40 of 43 patients) received platinum-based CTx with median four cycles (range, 2 to 6 cycles). Paclitaxel/carboplatin was most commonly used (16 patients), and cisplatin as a single agent was administered weekly in 11 patients. The other regimens were 5-fluorouracil/cisplatin (6 patients), gemcitabine/cisplatin (5 patients), docetaxel/cyclophosphamide (3 patients), and paclitaxel/cisplatin (2 patients). Concurrent CTx was omitted in seven patients, because of poor performance or refusal.

3. Clinical endpoint and statistical analysis
---------------------------------------------

The baseline for follow-up (BOF) was defined as the date of pathologic diagnosis of cervical cancer. DFS was the duration from BOF to the date of the most recent follow-up or the diagnosis date of recurrence. Recurrence was diagnosed through imaging studies; histologic confirmation was not mandatory. Recurrences were classified as locoregional failure (LRF) or distant failure (DF). LRF was defined as a failure in the intrapelvic and para-aortic areas, while DF was considered to be all relapses, except for LRF. OS was calcu lated from BOF to the date of the last follow-up or death. Survival data were collected through inquiries to the Resident Registration of the Ministry of Security and Public Administration of Republic of Korea.

Statistical analysis was performed using SPSS ver. 18 (SPSS Inc., Chicago, IL). DFS and OS curves were estimated using the Kaplan-Meier method, and the effects of each variable on survival were evaluated by log-rank tests. Multivariate analysis was performed using the Cox proportional hazard model with a backward conditional stepwise regression. The cut-off point for LODDs was selected based on the results of maximal chi-square method using R ver. 3.03. p-values of less than 0.05 were considered statistically significant.

Results
=======

Fifty patients with high-risk features were included and analyzed in this study. Median age of patients at diagnosis was 51 years (range, 27 to 78 years). Most patients (72%) were in FIGO stage IA/B. The most common histology was squamous cell carcinoma (76%). Other histologies included adenocarcinoma (7 patients), mucinous adenocarcinoma (2), adenosquamous carcinoma (1), glassy cell carcinoma (1), and mucoepidermoid carcinoma (1). Twelve patients showed no evidence of regional LN involvement. Other clinicopathologic factors are shown in [Table 1](#t1-crt-2015-085){ref-type="table"}.

The distribution of metastatic LNs in the 38 patients with positive LNs is shown in [Table 2](#t2-crt-2015-085){ref-type="table"}. The median number of positive LNs was two (range, 1 to 26), and involvement of obturator and external iliac LNs was most common. Thirteen patients (19.7%) had metastatic upper LNs, 12 common iliac LNs, and six para-aortic LNs. Of these six patients, only one had skip metastasis to para-aortic LN without involvement of common iliac LNs. The median value of LODDs was --1.15. Seventeen patients (34%) had ≥ 10% LNRs, and 22 (44%) ≥ --1.05 of LODDs.

During the adjuvant treatment, the most common acute complication was gastrointestinal toxicity (48%) followed by neutropenia (36%) and genitourinary toxicity (20%). These acute toxicities were resolved spontaneously within 3-4 months. Chronic lymphedema and peripheral neuropathy were reported in 36% and 10%, respectively. Two patients suffered from sustained urinary incontinence ([Table 3](#t3-crt-2015-085){ref-type="table"}).

1. Treatment failure
--------------------

The median follow-up duration was 80 months (range, 6 to 123 months). The estimated 5-year LRF-free survival rate was 89.5%, while the distant metastasis-free survival rate was 78.5%. Eleven patients (22%) experienced treatment failure. DF was dominant, occurring in 10 cases. Six cases were DF only, four were DF combined with LRF, and one was isolated LRF. The lungs were the most common site of DF (4 of 10 patients). Four simultaneous LRFs occurred in the RT field: the common iliac LN, paraaortic LN, bladder wall, and vaginal stump. These LRFs received at least 50.4 Gy, and up to 55.8 Gy were delivered to the para-aortic failure site by conventional fractionation. Isolated LRFs, which were not in the RT field, occurred in the lower vagina, adjacent to the vulva.

Among the 11 patients with treatment failure, five died a median of 10.6 months after failure. Two patients were still alive and receiving salvage CTx at the most recent follow-up, and the others (isolated DF, 2 patients; isolated LRF, 1 patient) were successfully salvaged and had maintained a state of no evidence of disease.

2. Analysis of DFS and OS
-------------------------

The 5-year DFS and OS rates were 76.1% and 86.4%, respectively. In univariate analysis for DFS ([Table 4](#t4-crt-2015-085){ref-type="table"}), perineural invasion (p \< 0.012), ≥ 2 LN metastasis (p=0.030), LNR ≥ 10% (p=0.003), upper LN metastasis (p=0.002), and ≥ --1.05 LODDs (p \< 0.001) ([Fig. 1A](#f1-crt-2015-085){ref-type="fig"}) were statistically significant unfavorable factors for DFS. Among the methods used for assessment of LN status, LODDs was the most powerful indicator associated with DFS. Lymphovascular invasion (LVI) and pN1 showed a trend toward poor DFS (LVI, p=0.053; pN1, p=0.059). Regarding OS, LODDs again was the only statistically significant prognostic factor (p=0.006) ([Fig. 1B](#f1-crt-2015-085){ref-type="fig"}). Neither preoperative tumor markers nor the preoperative neutrophil/lymphocyte ratio was a prognostic parameter for DFS or OS.

Subgroup analyses were performed to determine whether survival differences associated with LN status (number of positive LNs, LNR, upper LN metastasis, and LODDs) remained after separating patients with pN0 ([Fig. 2](#f2-crt-2015-085){ref-type="fig"}). The DFS curves of patients with single LN metastasis, LNR \< 10%, and only lower pelvic LN metastasis did not differ from those of patients with pN0. The DFS curve of patients with LODDs \< --1.05 was almost the same as that of pN0 ([Fig. 2A](#f2-crt-2015-085){ref-type="fig"}). Patients with LODDs ≥ --1.05 (5-year, 93.8% vs. 54.2%; p=0.015) ([Fig. 2A](#f2-crt-2015-085){ref-type="fig"}), upper LN metastasis (5-year, 83.1% vs. 46.2%; p=0.023) ([Fig. 2B](#f2-crt-2015-085){ref-type="fig"}), and LNR ≥ 10% (5-year, 84.4% vs. 52.3%; p=0.036) ([Fig. 2C](#f2-crt-2015-085){ref-type="fig"}) had significantly shorter DFS than those without these factors. Patients with ≥ 2 LN metastasis also had shorter DFS than those with single LN metastasis, but the difference was not statistically significant (5-year, 83.3% vs. 59.6%; p=0.204) ([Fig. 2D](#f2-crt-2015-085){ref-type="fig"}).

Variables with statistical significance in univariate analysis for DFS were included in multivariate analysis. In multivariate analysis, DFS was significantly affected by ≥ --1.05 LODDs (p=0.011; hazard ratio, 0.069; 95% confidence interval, 0.01 to 0.54), which was the only significant prognostic factor for DFS. The prognostic significance of location, ≥ 2 LNs metastasis, and LNR disappeared after adjusting for other factors.

Discussion
==========

Our data show that patients with LODDs ≥ --1.05 had significant risk for disease recurrence, specifically DF. Among the various methods used for assessment of LN state, LODDs was determined to be the strongest predictor of both recurrence and survival. However, other parameters related to LN status also seem to be important prognostic factors in patients with high risk cervical cancer as well as LODDs. The traditional prognostic factors suggested by surgical series, including bulky tumors, deep stromal invasion, resection margin involvement, PM invasion, and pN stage, did not predict the treatment outcomes in the current study. Their clinical impact might be attenuated by the adjuvant treatment.

In most solid tumors, N stages are categorized according to the number or region of pathologic LNs, which are well correlated with prognosis in general. In this context, many researchers have attempted to determine the clinical significance of nodal involvement of cervical cancer. For example, Monk et al. \[[@b10-crt-2015-085]\] demonstrated that patients with two or more positive LNs had a significantly lower survival rate after radical surgery followed by only postoperative RT (5-year OS, 55% vs. 79%; p=0.01). This unfavorable outcome was offset by the addition of CTx (5-year OS, 75% vs. 83%; p=0.37). Tsai et al. \[[@b5-crt-2015-085]\], who also reported the negative impact of two or more LNs on survival after adjuvant RT, and pointed to the significance of the location of positive LNs, categorized LNs as lower and upper LNs and showed that metastasis to upper LN was associated with a higher incidence of distant metastasis (50% vs. 16%, p=0.03). In similar results, Takeda et al. \[[@b14-crt-2015-085]\] reported that common iliac LNs significantly affected survival (5-year OS, approximately 40% vs. 80%; p=0.003) after adjuvant RT. When considering the hierarchical tendency of lymphatic spread in cervical cancer, the involvement of upper pelvic LN may worsen patients' treatment outcomes. However, in the current study, despite their significance in univariate analysis, the importance of metastasis to ≥ 2 LNs and upper LN disappeared in multivariate analysis. This change might be due to the close correlation between ≥ 2 LNs or upper LN metastasis and LODDs ≥ --1.05 (Fisher exact test, p \< 0.001).

Polterauer et al. \[[@b15-crt-2015-085]\] suggested LN density as an independent prognostic factor for DFS (p=0.01) and OS (p=0.05). Their definition of LN density was the same as the LNR in the current study, while the cut-off value was 10% based on a study of esophageal cancer. Our results of univariate analysis also showed a difference in DFS according to LNR. However, this prognostic significance was not observed in multivariate analysis, perhaps because of the close correlation of LNR to LODDs. All patients in the LNR ≥ 10% group were also included in the LODDs ≥ --1.05 group (Fisher exact test, p \< 0.001). Both the study by Polterauer et al. \[[@b15-crt-2015-085]\] and the current study were retrospective studies, which included a small number of patients. Therefore, a large prospective study is needed to address the significance of the LNR.

LODDs is not a familiar prognostic factor in cervical cancer. To the best of the authors' knowledge, the prognostic value of LODDs has not been tested in cervical cancer. The efficacy of LODDs in gastric and colorectal cancer was already reported in large scale studies and Wang et al. \[[@b16-crt-2015-085]\] demonstrated the prognostic superiority of LODDs to LNR. LODDs is a parameter requiring complex calculation and is less intuitive than LNR. However, LODDs' strength lies in their ability to discriminate patients with equal LNRs. In particular, Sun et al. \[[@b17-crt-2015-085]\] demonstrated that LODDs was still heterogeneous even though LNR was equal as 0 or 1. This finding suggested the potential of LODDs to distinguish different prognosis among patients with the same N stage.

In the current study, among the methods used for assessment of LN status, LODDs was the most powerful indicator associated with DFS. LODDs identified the subgroup that had a prognosis similar to that of patients with pN0, despite the presence of metastatic LNs ([Fig. 2A](#f2-crt-2015-085){ref-type="fig"}). Patients with LODDs ≥ --1.05 also had decreased OS. In addition, among 22 patients with LODDs ≥ --1.05, nine (40.9%) experienced DF. Similarly, 90% of patients with DF had a value of LODDs ≥ --1.05. These findings suggest that patients with LODDs ≥ --1.05 might have a high risk of DF and, therefore, should be considered for further systemic CTx.

In the current study, the majority of treatment failures were DF, consistent with the findings of previous studies reported in the literature \[[@b18-crt-2015-085],[@b19-crt-2015-085]\]. No relationship was observed between the RT field and the dose and recurrence site, and the incidence of LRF was acceptably low. These findings suggest that postoperative RT is delivered adequately. Further improvement of the outcomes might require strengthening CTx, instead of RT. Identification of patients at risk is important even after adjuvant RT or chemoradiotherapy. Kim et al. \[[@b20-crt-2015-085]\] proposed a nomogram for predicting the risk of recurrence in early-stage patients (I-IIA) after radical surgery with or without adjuvant treatment. This model is based on stage, number of pathologic LNs, PM invasion, and depth of invasion. Using similar variables, the Korean Radiation Oncology Group Study 13-03 more recently suggested a nomogram for prediction of OS after postoperative treatment \[[@b21-crt-2015-085]\]. However, these models have employed wellknown traditional factors identified only through surgical series. The newly emerging prognostic factors after completion of adjuvant treatment also need to be evaluated.

The current study has several limitations. First, many inherent biases stem from its nature as a retrospective study. Second, the number of patients studied might be not large enough to support definite conclusions. There is a probability that two or more LNs metastasis, upper LN involvement, or LNR ≥ 10% also has clinical significance in consideration of statistical correlation of these parameters with LODDs. Although LODDs was the most meaningful factor in the result of multivariate analysis, it should be validated through study comprising more patients. Finally, the study population contained adjuvant RT only groups in spite of high risk features, which caused treatment heterogeneity. However, conversely, this study population is more realistic than CCRT alone in this clinical setting. The literature has dealt little with LODDs as an important prognostic factor, thus this study is the first to demonstrate the prognostic value of LODDs in patients with cervical cancer.

Conclusion
==========

In conclusion, LODDs ≥ --1.05 is an independent prognostic factor for DFS in high-risk patients who underwent radical surgery followed by adjuvant treatment. OS also showed a significant decrease in patients with LODDs ≥ --1.05. Among the various methods used for assessment of LN status, LODDs was the most powerful predictor associated with both recurrence and OS. Therefore, considering the high rate of DF, intensified CTx might be required in patients with LODDs ≥ --1.05.
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###### 

Clinical characteristics

  Characteristic                                                                                No. (%)
  --------------------------------------------------------------------------------------------- -----------------------
  **Age, median (range, yr)**                                                                   51 (27 to 78)
  **FIGO stage**                                                                                
   1A2                                                                                          2 (4.0)
   1B1                                                                                          24 (48.0)
   1B2                                                                                          10 (20.0)
   2A1                                                                                          9 (18.0)
   2A2                                                                                          1 (2.0)
   2B                                                                                           4 (8.0)
  **Histology**                                                                                 
   Squamous cell carcinoma                                                                      38 (76.0)
   Adenocarcinoma                                                                               7 (14.0)
   Mucinous adenocarcinoma                                                                      2 (4.0)
   Adenosquamous carcinoma                                                                      1 (2.0)
   Glassy cell carcinoma                                                                        1 (2.0)
   Mucoepidermoid carcinoma                                                                     1 (2.0)
  **Deep stromal invasion (outer 1/3)**                                                         
   Negative                                                                                     6 (12.0)
   Positive                                                                                     35 (70.0)
  **Parametrial extension**                                                                     
   Negative                                                                                     20 (40.0)
   Positive                                                                                     30 (60.0)
  **Bulky tumor (cm)**                                                                          
   ≤ 4                                                                                          21 (42.0)
   \> 4                                                                                         29 (58.0)
  **Lymphovascular invasion**                                                                   
   Negative                                                                                     11 (22.0)
   Positive                                                                                     39 (78.0)
  **Perineural invasion**                                                                       
   Negative                                                                                     43 (86.0)
   Positive                                                                                     7 (14.0)
  **Pathologic N stage**                                                                        
   N0                                                                                           12 (24.0)
   N1                                                                                           38 (76.0)
  **Upper lymph node^[a)](#tfn2-crt-2015-085){ref-type="table-fn"}^ involvement**               
   Negative                                                                                     37 (74.0)
   Positive                                                                                     13 (26.0)
  **LN ratio (%)^[b)](#tfn3-crt-2015-085){ref-type="table-fn"}^**                               
   \< 10                                                                                        33 (66.0)
   ≥ 10                                                                                         17 (34.0)
  **Log odds of positive LNs^[c)](#tfn4-crt-2015-085){ref-type="table-fn"}^, median (range)**   -1.15 (-2.09 to -0.2)
   ≥ -1.05                                                                                      22 (44.0)
   \< -1.05                                                                                     28 (56.0)
  **Pretreatment NLR, median (range)**                                                          2.09 (0.72 to 18.89)
   \< 2.1                                                                                       25 (50.0)
   ≥ 2.1                                                                                        24 (48.0)
  **Adjuvant treatment**                                                                        
   RT alone                                                                                     7 (14.0)
   CCRT                                                                                         43 (86.0)
  **SCC, median (U/mL)**                                                                        2.60
  **CEA, median (ng/mL)**                                                                       1.07

FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node; NLR, neutrophil/lymphocyte ratio; RT, radiotherapy; CCRT, concurrent chemoradiotherapy; SCC, squamous cell carcinoma antigen; CEA, carcinoembryonic antigen.

Upper lymph node: common iliac or para-aortic lymph node,

LN ratio: No. of pathologic LNs/No. of total LNs harvested,

Log odds of positive LNs: log(No. of positive LNs/No. of negative LNs).

###### 

Distribution of metastatic lymph nodes (LNs) in patients with pN1 (n=38)

                                      Distribution of pathologic LN          No. (%)
  ----------------------------------- -------------------------------------- ------------
  Pelvic node dissection              Total harvested node, median (range)   30 (10-79)
                                      Pathologic node, median (range)        2 (1-26)
                                      Obturator LN                           19 (50.0)
                                      External iliac LN                      15 (41.7)
                                      Internal iliac LN                      12 (31.6)
                                      Common iliac                           12 (31.6)
                                      Parametrial LN                         3 (7.9)
  Para-aortic LN examination (n=13)   Total harvested node, median (range)   6 (1-17)
  Pathologic node, median (range)     1 (0-9)                                
  Para-aortic LN                      7 (18.4)                               

###### 

Treatment toxicity

  Toxicity                     Grade 1/2   Grade 3   Grade 4
  ---------------------------- ----------- --------- ---------
  **Acute**                                          
   Gastrointestinal toxicity   24 (48)     \-        \-
   Genitourinary toxicity      10 (20)     \-        \-
   Neutropenia                 13 (26)     4 (8)     14 (28)
  **Chronic**                                        
   Lymphedema                  18 (36)     \-        \-
   Peripheral neuropathy       5 (10)      \-        \-
   Urinary incontinence        2 (4)       \-        \-

Values are presented as number (%). Two patients underwent surgical intervention for adhesive ileus or vesicovaginal fistula.

###### 

Univariate analysis for disease-free survival (DFS) and overall survival (OS)

  Variable                                                                       5-yr DFS (%)   p-value^[a)](#tfn8-crt-2015-085){ref-type="table-fn"}^   5-yr OS (%)   p-value^[a)](#tfn8-crt-2015-085){ref-type="table-fn"}^
  ------------------------------------------------------------------------------ -------------- -------------------------------------------------------- ------------- --------------------------------------------------------
  **Age (yr)**                                                                                                                                                         
   ≤ 50                                                                          78.0           0.831                                                    91.4          0.460
   \> 50                                                                         74.1                                                                    82.5          
  **Histology**                                                                                                                                                        
   Squamous cell carcinoma                                                       74.3           0.718                                                    85.0          0.724
   Others                                                                        83.3                                                                    91.7          
  **Deep stromal invasion**                                                                                                                                            
   Negative                                                                      100            0.149                                                    100           0.311
   Positive                                                                      69.0                                                                    83.4          
  **Bulky tumor (cm)**                                                                                                                                                 
   ≤ 4                                                                           78.6           0.686                                                    82.4          0.700
   \> 4                                                                          74.5                                                                    88.7          
  **Lymphovascular invasion**                                                                                                                                          
   Negative                                                                      100            0.053                                                    100           0.157
   Positive                                                                      69.1                                                                    82.2          
  **Parametrial invasion**                                                                                                                                             
   Negative                                                                      89.1           0.084                                                    95.0          0.195
   Positive                                                                      67.3                                                                    79.8          
  **Perineural invasion**                                                                                                                                              
   Negative                                                                      82.2           0.012                                                    87.0          0.801
   Positive                                                                      38.1                                                                    83.3          
  **Pathologic N stage**                                                                                                                                               
   N0                                                                            100            0.059                                                    100           0.197
   N1                                                                            69.6                                                                    83.0          
  **No. of LN invasion**                                                                                                                                               
   \< 2                                                                          90.0           0.030                                                    87.0          0.801
   ≥ 2                                                                           59.6                                                                    83.3          
  **Upper LN^[b)](#tfn9-crt-2015-085){ref-type="table-fn"}^ involvement**                                                                                              
   Negative                                                                      88.2           0.002                                                    90.8          0.197
   Positive                                                                      46.2                                                                    75.0          
  **LN ratio (%)^[c)](#tfn10-crt-2015-085){ref-type="table-fn"}^**                                                                                                     
   \< 10                                                                         89.7           0.003                                                    92.8          0.092
   ≥ 10                                                                          52.3                                                                    75.3          
  **Log odds of positive LNs^[d)](#tfn11-crt-2015-085){ref-type="table-fn"}^**                                                                                         
   ≥ -1.05                                                                       54.2           \< 0.001                                                 71.5          0.006
   \< -1.05                                                                      96.4                                                                    100           
  **Pretreatment NLR**                                                                                                                                                 
   \< 2.1                                                                        74.0           0.646                                                    85.8          0.875
   ≥ 2.1                                                                         83.3                                                                    86.8          
  **SCC**                                                                                                                                                              
   ≤ 2                                                                           87.8           0.145                                                    93.8          0.256
   \> 2                                                                          72.1                                                                    82.3          

LN, lymph node; NLR, neutrophil/lymphocyte ratio; SCC, squamous cell carcinoma antigen.

p-value by log-rank test,

Upper LN included common iliac or para-aortic lymph node,

LN ratio: No. of pathologic LNs/No. of total LNs harvested,

Log odds of positive LNs: log(No. of positive LNs/No. of negative LNs).
